Alpine Global Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Alpine Global Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,091	Closed	-$238K	–	356
2021 Q1	$238K	Buy	+2,091	New	+$285K	0.02%	226

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alpine Global Management's RARE Position: Q2 2021 in Review

Alpine Global Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 2,091 shares — an estimated $238K sold.

Alpine Global Management first reported a position in RARE in Q1 2021 and held it in 1 quarter. The position peaked at $238K in Q1 2021. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Alpine Global Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Alpine Global Management sold 2,091 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $238K.
Alpine Global Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 1 quarter.
Alpine Global Management's Ultragenyx Pharmaceutical position peaked at $238K in Q1 2021.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Alpine Global Management's 13F filing for Q2 2021, filed 13 Aug 2021.